166 related articles for article (PubMed ID: 37382687)
1. FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest.
Pan Q; Wang Q; Zhao T; Zhao X; Liang Y; Shi M; Chen C; Lin F
Med Oncol; 2023 Jun; 40(8):215. PubMed ID: 37382687
[TBL] [Abstract][Full Text] [Related]
2. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Shah NR; Tancioni I; Ward KK; Lawson C; Chen XL; Jean C; Sulzmaier FJ; Uryu S; Miller NL; Connolly DC; Schlaepfer DD
Gynecol Oncol; 2014 Jul; 134(1):104-11. PubMed ID: 24786638
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
[TBL] [Abstract][Full Text] [Related]
4. C1632 inhibits ovarian cancer cell growth and migration by inhibiting LIN28 B/let-7/FAK signaling pathway and FAK phosphorylation.
Zhang Q; Shi M; Zheng R; Han H; Zhang X; Lin F
Eur J Pharmacol; 2023 Oct; 956():175935. PubMed ID: 37541366
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Kanteti R; Mirzapoiazova T; Riehm JJ; Dhanasingh I; Mambetsariev B; Wang J; Kulkarni P; Kaushik G; Seshacharyulu P; Ponnusamy MP; Kindler HL; Nasser MW; Batra SK; Salgia R
Cancer Biol Ther; 2018 Apr; 19(4):316-327. PubMed ID: 29303405
[TBL] [Abstract][Full Text] [Related]
6. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis.
Ozmadenci D; Shankara Narayanan JS; Andrew J; Ojalill M; Barrie AM; Jiang S; Iyer S; Chen XL; Rose M; Estrada V; Molinolo A; Bertotto T; Mikulski Z; McHale MC; White RR; Connolly DC; Pachter JA; Kuchroo VK; Stupack DG; Schlaepfer DD
Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2117065119. PubMed ID: 35467979
[TBL] [Abstract][Full Text] [Related]
7. Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage.
Xiao H; Wu Z; Wang Q; Zhou C; Lu F; Xiao Y
Anticancer Res; 2023 Jan; 43(1):389-403. PubMed ID: 36585202
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
[TBL] [Abstract][Full Text] [Related]
9. A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation.
Jin XX; Mei YN; Shen Z; Zhu JF; Xing SH; Yang HM; Liang G; Zheng XH
Phytomedicine; 2022 Jul; 101():154087. PubMed ID: 35429924
[TBL] [Abstract][Full Text] [Related]
10. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase.
Hu XW; Meng D; Fang J
Carcinogenesis; 2008 Dec; 29(12):2369-76. PubMed ID: 18974065
[TBL] [Abstract][Full Text] [Related]
11. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
[TBL] [Abstract][Full Text] [Related]
12. Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration.
Al-Ghabkari A; Qasrawi DO; Alshehri M; Narendran A
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1461-1469. PubMed ID: 31006845
[TBL] [Abstract][Full Text] [Related]
13. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.
Sood AK; Coffin JE; Schneider GB; Fletcher MS; DeYoung BR; Gruman LM; Gershenson DM; Schaller MD; Hendrix MJ
Am J Pathol; 2004 Oct; 165(4):1087-95. PubMed ID: 15466376
[TBL] [Abstract][Full Text] [Related]
14. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.
Selvendiran K; Ahmed S; Dayton A; Ravi Y; Kuppusamy ML; Bratasz A; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Mol Cancer Res; 2010 Sep; 8(9):1188-97. PubMed ID: 20713491
[TBL] [Abstract][Full Text] [Related]
15. FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.
Tancioni I; Uryu S; Sulzmaier FJ; Shah NR; Lawson C; Miller NL; Jean C; Chen XL; Ward KK; Schlaepfer DD
Mol Cancer Ther; 2014 Aug; 13(8):2050-61. PubMed ID: 24899686
[TBL] [Abstract][Full Text] [Related]
16. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways.
Badgwell DB; Lu Z; Le K; Gao F; Yang M; Suh GK; Bao JJ; Das P; Andreeff M; Chen W; Yu Y; Ahmed AA; S-L Liao W; Bast RC
Oncogene; 2012 Jan; 31(1):68-79. PubMed ID: 21643014
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Ward KK; Tancioni I; Lawson C; Miller NL; Jean C; Chen XL; Uryu S; Kim J; Tarin D; Stupack DG; Plaxe SC; Schlaepfer DD
Clin Exp Metastasis; 2013 Jun; 30(5):579-94. PubMed ID: 23275034
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
[TBL] [Abstract][Full Text] [Related]
19. Targeting of PFKFB3 with miR-206 but not mir-26b inhibits ovarian cancer cell proliferation and migration involving FAK downregulation.
Boscaro C; Baggio C; Carotti M; Sandonà D; Trevisi L; Cignarella A; Bolego C
FASEB J; 2022 Mar; 36(3):e22140. PubMed ID: 35107852
[TBL] [Abstract][Full Text] [Related]
20. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
